MRI Guided Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma to Enhance Complete Response
Overview
- Phase
- Early Phase 1
- Intervention
- Capecitabine
- Conditions
- Rectal Adenocarcinoma
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Feasibility of MRI guided dose adaptive chemoradiation therapy
- Status
- Active, not recruiting
- Last Updated
- last month
Overview
Brief Summary
The purpose of the study is to determine the feasibility of using magnetic resonance imaging (MRI)-guided adaptive chemoradiation therapy to improve response to treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Eastern Cooperative Oncology Group (ECOG) Performance status of 0, 1
- •Histologically confirmed diagnosis of adenocarcinoma of the rectum.
- •Clinical Stage II or III as determined on rectal MRI with a distal tumor extent/margin no more than 1 cm proximal to the anterior peritoneal reflection.
- •Must have the ability to swallow and retain oral medications
- •Adequate hematologic function within 28 days before registration as defined in protocol.
- •Adequate hepatic function within 45 days before registration, as defined in protocol.
- •Adequate renal function within 28 days before registration, as defined in protocol.
- •International normalized ratio of prothrombin time (INR) and prothrombin time (PT) within 28 days before registration must be within normal limits for the lab. Patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history
- •Pregnancy test done within 14 days before registration must be negative (for women of childbearing potential only). Pregnancy testing should be performed according to institutional standards.
Exclusion Criteria
- •Patients with one or more of the following conditions are NOT eligible for this study:
- •Rectal cancer histology other than adenocarcinoma (i.e., sarcoma, lymphoma, squamous cell carcinoma, mucosal melanoma, mixed adenoneuroendocrine, anal adenocarcinoma, etc.).
- •History of prior invasive rectal malignancy, regardless of disease-free interval or history of familial polyposis syndrome (Lynch, FAP, etc.).
- •Patients with a history of antineoplastic treatment for prior malignancy within the past 3 years, except for adequately treated basal cell skin carcinoma or in situ cervical cancer. Note: Hormone therapy for breast cancer is permitted.
- •Primary unresectable rectal cancer. Note: A tumor is considered unresectable when invading adjacent organs and an en bloc resection will not achieve negative margins.
- •Synchronous colorectal adenocarcinomas.
- •Tumor may not be causing symptomatic bowel obstruction
- •Definitive clinical or radiologic evidence of metastatic disease or nodal disease outside of the prescribed radiation field. Note: Required imaging studies must have been performed within 28 days prior to enrollment.
- •Patients with a history of an arterial thrombotic event within the past 6 months. This includes angina (stable or unstable), myocardial infarction, transient ischemic attack (TIA), Cardiovascular Accident (CVA). Note: Patients with a history of venous thrombotic episodes such as deep venous thrombosis, pulmonary embolus occurring more than 6 months prior to enrollment may be considered for protocol participation, provided they are on stable doses of anticoagulant therapy. Similarly, patients who are anticoagulated for atrial fibrillation or other conditions may participate, provided they are on stable doses of anticoagulant therapy.
- •No other experimental therapies (including chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, matric metalloprotease inhibitors, thalidomide, anti-VEGF (vascular endothelial growth factor) monoclonal antibody or other experimental drugs) of any kind are permitted while the patient is receiving study treatment.
Arms & Interventions
MRI-guided adaptive radiation
Patients will receive capecitabine-based chemoradiotherapy (chemotherapy with capecitabine + radiation). Dosing will be modified based on tumor changes measured daily and weekly by MR-guided radiotherapy (MRgRT) utilizing MR-linac (MRL) systems. Chemoradiotherapy will be followed by standard of care consolidated chemotherapy. (FOLFOX)
Intervention: Capecitabine
MRI-guided adaptive radiation
Patients will receive capecitabine-based chemoradiotherapy (chemotherapy with capecitabine + radiation). Dosing will be modified based on tumor changes measured daily and weekly by MR-guided radiotherapy (MRgRT) utilizing MR-linac (MRL) systems. Chemoradiotherapy will be followed by standard of care consolidated chemotherapy. (FOLFOX)
Intervention: Radiation Therapy
MRI-guided adaptive radiation
Patients will receive capecitabine-based chemoradiotherapy (chemotherapy with capecitabine + radiation). Dosing will be modified based on tumor changes measured daily and weekly by MR-guided radiotherapy (MRgRT) utilizing MR-linac (MRL) systems. Chemoradiotherapy will be followed by standard of care consolidated chemotherapy. (FOLFOX)
Intervention: FOLFOX regimen
Outcomes
Primary Outcomes
Feasibility of MRI guided dose adaptive chemoradiation therapy
Time Frame: Up to 6 weeks
Investigators will demonstrate if MRI guided dose-adaptation based on MR morphologic objective measurements during primary chemoradiation is feasible. Feasibility will be recorded for each patient as an indicator variable (1=feasible; 0=not feasible)
Secondary Outcomes
- Number of Participants with Complete Clinical Response (cCR)(Up to 6 months)
- Number of Participants with Pathological Complete Response (pCR)(Up to 6 months)